CTLA4 and metastatic melanoma: In the larger cohort of 115 patients treated with anti–CTLA-4 agent for metastatic melanoma, 85% showed an increased chronic and neutrophilic inflammatory infiltrate within the lamina propria, without chronic architectural changes in the majority of cases (61%).